Banca Mediolanum (BMED) Q3 2024 earnings summary
Event summary combining transcript, slides, and related documents.
Q3 2024 earnings summary
15 Jan, 2026Executive summary
Achieved record-breaking financial results for the first nine months of 2024, with net income up 18% year-over-year and double-digit growth across all key business lines.
Net inflows reached €7.16 billion, up 28% year-over-year, with managed asset inflows nearly doubling to €5.44 billion (+92%).
Total assets under management rose to €133 billion, a 13%–18% increase since the start of the year.
Customer base grew 5% to over 1.89 million, with 149,000 new customers acquired and strong digital acquisition.
The board approved an interim dividend of €0.37 per share, payable from November 20, 2024.
Financial highlights
Net commission income rose 13% to over €873 million; recurring fees increased 14.5% to €1.13 billion.
Net interest income (NII) was €613.4 million, up 13% year-over-year.
Operating margin reached a record €848 million, up 16% year-over-year; contribution margin up 15% to €1,481.8 million.
Net income for the period was €674.3 million, an 18% increase from the same period in 2023.
Cost/income ratio improved to 38.3%; annualised cost of risk at 21 basis points.
Outlook and guidance
2024 guidance for net inflows into managed assets raised to €7.5 billion, with similarly strong volumes anticipated for 2025.
Net interest income expected to grow by 8% in 2024, with a projected 3% decrease in 2025 due to market yield curve expectations.
Cost/income ratio for 2024 expected below 40%; dividend for 2024 anticipated to increase versus the previous year.
Performance fees accrued but not crystallized as of November 5th amounted to €230 million.
2024 is projected to be the best year yet, with robust inflows and asset growth supporting future recurring revenues.
Latest events from Banca Mediolanum
- Record net income, strong asset growth, and a 25% higher dividend highlight a standout year.BMED
Q4 20253 Feb 2026 - Net income up 24% to EUR 449.9M, assets under administration EUR 129.5B, CET1 at 23.7%.BMED
Q2 20242 Feb 2026 - Record net income of €1.12B, €10.44B inflows, and 42% higher dividend proposed.BMED
Q4 20248 Jan 2026 - Net income up 10% YoY, record inflows, and strong capital ratios support 2025 outlook.BMED
Q1 20258 Jan 2026 - Net income up 8% to €726M, assets at €150.4B, and interim dividend raised to €0.60/share.BMED
Q3 20258 Nov 2025 - Net income up 6% to €477.3M, with record assets, strong inflows, and robust capital ratios.BMED
Q2 20251 Nov 2025